4//SEC Filing
Burnett Patrick 4
Accession 0001787306-25-000106
CIK 0001787306other
Filed
Jul 13, 8:00 PM ET
Accepted
Jul 14, 4:02 PM ET
Size
372.0 KB
Accession
0001787306-25-000106
Insider Transaction Report
Form 4
Burnett Patrick
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-07-10+23,000→ 138,468 total - Exercise/Conversion
Common Stock
2025-07-14+5,750→ 121,218 total - Exercise/Conversion
Stock Option (right to buy)
2025-07-10−23,000→ 178,250 totalExercise: $3.64Exp: 2034-01-12→ Common Stock (23,000 underlying) - Sale
Common Stock
2025-07-10$15.05/sh−23,000$346,047→ 115,468 total - Sale
Common Stock
2025-07-14$15.07/sh−5,750$86,654→ 115,468 total - Exercise/Conversion
Stock Option (right to buy)
2025-07-14−5,750→ 172,500 totalExercise: $3.64Exp: 2034-01-12→ Common Stock (5,750 underlying)
Footnotes (4)
- [F1]The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.
- [F2]The transaction was executed in multiple trades in prices ranging from $15.00 to $15.125, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]The transaction was executed in multiple trades in prices ranging from $15.00 to $15.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
Issuer
Arcutis Biotherapeutics, Inc.
CIK 0001787306
Entity typeother
Related Parties
1- filerCIK 0001741987
Filing Metadata
- Form type
- 4
- Filed
- Jul 13, 8:00 PM ET
- Accepted
- Jul 14, 4:02 PM ET
- Size
- 372.0 KB